Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma

Ajai ChariIcahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA; Correspondence[email protected]

Sarah LarsonUniversity of California, Los Angeles, CA, USA;

Beata HolkovaVirginia Commonwealth University Medical Center, Richmond, VA, USA;

Robert F. CornellVanderbilt-Ingram Cancer Center, Nashville, TN, USA;

Cristina GasparettoDuke University Medical Center, Durham, NC, USA;

Chatchada KaranesCity of Hope National Medical Center, Duarte, CA, USA;

Jeffrey V. MatousColorado Blood Cancer Institute, Denver, CO, USA;

Ruben NiesvizkyWeill Cornell Medical College, New York, NY, USA;

Jason ValentCleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA;

Matthew LunningUniversity of Nebraska Medical Center, Omaha, NE, USA;

Saad Z. UsmaniLevine Cancer Institute/Carolinas Healthcare System, Charlotte, NC, USA;

Larry D. Anderson JrSimmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA;

Lipo ChangPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA;

Yihua LeePharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA;

Yvonne PakPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA;

Zeena SalmanPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA;

Thorsten GraefPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA;

Elizabeth BilottiPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA;

Saurabh ChhabraMedical University of South Carolina, Charleston, SC, USA

References